Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Glioblastoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Mouth Neoplasms 2Leukemia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hyperthermia 2

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Castration-resistant Prostate Cancer Patients with Oligometastases × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡